No Data
No Data
Hang Seng Index: Benefiting from policy support, biotechnology stocks have seen three consecutive months of inflows.
The Hang Seng Index company stated that there are signs of improvement in the recent situation of biotechnology stocks, as well as benefitting from policy support and three consecutive months of inflow of funds.
China Securities Co., Ltd.: Q2 albumin batch issuance is the same as last year, and hepatitis B batch issuance has resumed growth.
The blood product industry is expected to maintain steady growth in the first half of 24H1. In the second half of the year, the industry is expected to continue the tight supply and demand pattern. The leading companies in the industry are expected to achieve continuous increase in plasma collection and profitability, and have more competitive advantages.
Biosino Bio-Tec (08247): He Xin was appointed as an independent non-executive director.
Biosino Bio-Tec (08247) announced that the appointment of He Xin as an independent non-executive director, as well as a member of the audit committee, nomination committee and remuneration committee, has been approved by the shareholders at the anniversary general meeting and will take effect on June 28, 2024. In addition, Fan Hua has been appointed as a supervisor to replace Li Jifeng, effective from June 28, 2024, after gaining approval from the shareholders at the anniversary general meeting.
Benign Growth For Biosino Bio-Technology and Science Incorporation (HKG:8247) Underpins Stock's 26% Plummet
Biosino Bio-Tec (08247) recommends appointing Fan Hua as a shareholder representative supervisor.
Biosino Bio-Tech (08247) announced that He Xin, who holds approximately 7.83% of the company's issued share capital...
Biosino Bio-Technology and Science Incorporation (HKG:8247) Shares Fly 68% But Investors Aren't Buying For Growth
No Data